Thus, the effect of IFNγ on tumor cell response to CAR-T therapy will not only depend on context and timing but also the ability of tumors cells to induce inhibitory receptors like HLA-E in response to inflammatory signals, as well as their general sensitivity to IFNγ-mediated death. The gene discussed is HLA-E; the disease is neoplasm.